हिंदी में पढ़ें

Add Zee Business As A Preferred Source

Home
/Cipla

Cipla

Cipla Q2 Results Today: Net profit up 4% YoY to Rs 1,351 crore, revenue grows 8%

Cipla Q2 Results Today: Net profit up 4% YoY to Rs 1,351 crore, revenue grows 8%

Thu, October 30, 2025

Newsbreak Confirmed: What to make of Cipla's Yurpeak pact with Eli Lilly? Nuvama raises target by Rs 74

Newsbreak Confirmed: What to make of Cipla's Yurpeak pact with Eli Lilly? Nuvama raises target by Rs 74

Fri, October 24, 2025

Cipla in talks with Eli Lilly for diabetes drug, say sources; shares in green

Cipla in talks with Eli Lilly for diabetes drug, say sources; shares in green

Mon, August 25, 2025

Cipla Q1 FY26 Results: With Rs 1,298 crore Q1 profit, Mumbai-based drug maker beats Street estimates; margin steady

Cipla Q1 FY26 Results: With Rs 1,298 crore Q1 profit, Mumbai-based drug maker beats Street estimates; margin steady

Fri, July 25, 2025

Cipla Q4FY25 Results Preview: Strong show seen with margin boost; US biz, gRevlimid key triggers

Cipla Q4FY25 Results Preview: Strong show seen with margin boost; US biz, gRevlimid key triggers

Tue, May 13, 2025

Pharma stocks under pressure: Sun Pharma cracks 5%, Nifty Pharma down 2% after Trump’s big blow on US drug pricing

Pharma stocks under pressure: Sun Pharma cracks 5%, Nifty Pharma down 2% after Trump’s big blow on US drug pricing

Mon, May 12, 2025

RECOMMENDED

Trump’s pharma order spooks Indian drug makers; Anil Singhvi expects one stock to lead rebound

Trump’s pharma order spooks Indian drug makers; Anil Singhvi expects one stock to lead rebound

Tue, May 6, 2025

Trump’s Pharma Tariff Threat Looms: What it could mean for Indian drug makers

Trump’s Pharma Tariff Threat Looms: What it could mean for Indian drug makers

Thu, April 10, 2025

Pharma Stocks Crash: Gland, Aurobindo, Biocon, Sun Pharma slump up to 6% as Trump eyes import tariffs

Pharma Stocks Crash: Gland, Aurobindo, Biocon, Sun Pharma slump up to 6% as Trump eyes import tariffs

Wed, April 9, 2025

Nifty Pharma plunges 6% as US tariff fears hammer exports; Gland Pharma, Divi's Labs tumble 11%

Nifty Pharma plunges 6% as US tariff fears hammer exports; Gland Pharma, Divi's Labs tumble 11%

Mon, April 7, 2025

Will Trump’s new tariffs spell trouble for Indian pharma stocks?

Will Trump’s new tariffs spell trouble for Indian pharma stocks?

Fri, April 4, 2025

Stocks To Buy For 2 Weeks: Analysts bullish on largecap, midcap scrips for short term; MCX, Cipla on the list

Stocks To Buy For 2 Weeks: Analysts bullish on largecap, midcap scrips for short term; MCX, Cipla on the list

Thu, February 13, 2025

Pharma stocks decline as Nifty Pharma index slips 2%; Alkem, Ipca, Divi’s lead losses

Pharma stocks decline as Nifty Pharma index slips 2%; Alkem, Ipca, Divi’s lead losses

Mon, February 10, 2025

Union Budget 2025: Healthcare sector gets Rs 98,311 crore; pharma stocks in focus

Union Budget 2025: Healthcare sector gets Rs 98,311 crore; pharma stocks in focus

Sat, February 1, 2025

Cipla Q3 Results: Pharmaceutical company's net profit rises 49% to Rs 1,575 crore, revenue up 7%

Cipla Q3 Results: Pharmaceutical company's net profit rises 49% to Rs 1,575 crore, revenue up 7%

Tue, January 28, 2025

Promoters Samina and Rumana Hamied exit Cipla; sell 1.72% stake for Rs 2,111 crore

Promoters Samina and Rumana Hamied exit Cipla; sell 1.72% stake for Rs 2,111 crore

Mon, December 2, 2024

Cipla Block Deal News: Cipla promoters offload 1.72% stake via block deals at 6% discount

Cipla Block Deal News: Cipla promoters offload 1.72% stake via block deals at 6% discount

Mon, December 2, 2024

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

Thu, October 31, 2024

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets

Thu, October 31, 2024

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

Tue, October 29, 2024

1
2
3
4
5

Top News